[Dipeptidyl-peptidase 4 inhibitors in patients with prediabetes or metabolic syndrome]
Argento F, Bardach A, Alfie V, Rojas C, Klappenbach R, Ciapponi A, García Martí S, Pichon Riviere A, Augustovski F
Record ID 32018002313
Spanish
Original Title:
Inhibidores de dipeptidil-peptidasa 4 en pacientes con prediabetes o síndrome metabólico
Authors' recommendations:
Very low-quality evidence does not allow to draw conclusions on the efficacy and safety of dipeptidyl-peptidase 4 inhibitors (DPP4) in patients with prediabetes or metabolic syndrome without diabetes mellitus (DM). There are promising results regarding significant outcomes, such as a decrease in the incidence of type 2 DM or return to normal glucose levels, with the use of DPP4 inhibitors in combination with metformin versus metformin alone in prediabetic patients. However, at present the methodological limitations of the evidence found does not allow to give a recommendation on the use of dipeptidyl-peptidase 4 inhibitors for this indication. The Argentine National Practice Guidelines on Prevention, Diagnosis and Treatment of Type 2 Diabetes Mellitus and the scientific societies such as the American Association of Clinical Endocrinologists, the American Diabetes Association and the Canadian Diabetes Association, recommend metformin if a drug needs to be administered to a patient with prediabetes, but they do not mention DPP4 inhibitors for this population. The Latin American Diabetes Association states that both metformin and DPP4 inhibitors, among other drugs, are potential treatments for patients with prediabetes. Argentina’s National Administration of Drugs, Foods and Medical Devices, the United States Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products, have not approved its use in patients with prediabetes or metabolic syndrome. Also, several health sponsors from Europe and United States cover this drug for patients with type 2 DM, but they do not consider its use for other populations, whereas the official agencies of most Latin-American countries do not cover it in any of these indications.
Details
Project Status:
Completed
Year Published:
2021
URL for published report:
https://www.iecs.org.ar/publicacion/?id=20393
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Prediabetic State
- Metabolic Syndrome
- Dipeptidyl Peptidase 4
- Dipeptidyl-Peptidase IV Inhibitors
- Hypoglycemic Agents
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.